GGT (γ -glutamyl transpeptidase) is an essential enzyme for maintaining cysteine homoeostasis, leukotriene synthesis, metabolism of glutathione conjugates and catabolism of extracellular glutathione. Overexpression of GGT has been implicated in many pathologies, and clinical inhibitors of GGT are under development for use in the treatment of asthma, cancer and other diseases. Inhibitors are generally characterized using synthetic GGT substrates. The present study of uncompetitive inhibitors of GGT, has revealed that the potency with which compounds inhibit GGT activity in the standard biochemical assay does not correlate with the potency with which they inhibit the physiological reaction catalysed by GGT. Kinetic studies provided insight into the mechanism of inhibition. Modifications to the sulfobenzene or distal benzene ring of the uncompetitive inhibitor OU749 affected activity. One of the most potent inhibitors was identified among a novel group of analogues with an amine group para on the benzosulfonamide ring. New more potent uncompetitive inhibitors of the physiological GGT reaction were found to be less toxic than the glutamine analogues that have been tested clinically. Development of non-toxic inhibitors is essential for exploiting GGT as a therapeutic target.
INTRODUCTION
GGT (γ -glutamyl transpeptidase; UniProt number P19440, EC 2.3.2.2) is a cell-surface enzyme that cleaves γ -glutamyl bonds of extracellular substrates including glutathione (GSH), GSH S-conjugates and leukotriene C 4 [1] [2] [3] . Catabolism of GSH by GGT affects intracellular redox levels and cysteine homoeostasis [4, 5] . GGT cleavage of GSH S-conjugates alters drug toxicity and inflammation [6] [7] [8] . Overexpression of GGT has been implicated in pulmonary disease, cardiovascular disease and cancer [9] [10] [11] . Therefore development of potent inhibitors of hGGT (human GGT) for clinical use is predicted to have broad therapeutic impact. Currently, the most potent GGT inhibitors are glutamine analogues [12, 13] . Glutamine analogues that inhibit GGT and have been evaluated in humans are too toxic for clinical use [14] [15] [16] . We previously identified a new class of uncompetitive inhibitors of hGGT that are considerably less toxic than the glutamine analogues [17, 18] .
The reaction catalysed by GGT in vivo is the hydrolysis of the γ -glutamyl bond. GGT hydrolyses GSH into glutamate and cysteinylglycine [1, 2] . The γ -glutamyl substrate (donor substrate) binds to GGT, which initiates a nucleophilic attack on the γ -glutamyl bond ( Figure 1A ). An acyl bond is formed between the oxygen on the side chain of Thr 381 of hGGT and the γ -glutamyl group of the substrate, creating the γ -glutamyl enzyme intermediate (F-form of the enzyme) [19] . The acyl bond is hydrolysed by water to release glutamate and cysteinyl-glycine. The reaction is a modified Ping Pong reaction [1] . The addition of high concentrations of dipeptide or amino acid acceptor molecules (second substrate for the Ping Pong reaction) results in a transpeptidation reaction ( Figure 1B ). The free α-amine on the acceptor attacks the acyl bond, transferring the γ -glutamyl group to the acceptor, thereby forming a new γ -glutamyl compound [20] .
The most commonly used assay for GGT activity monitors the transpeptidation reaction with the synthetic compound LGpNA (L-γ -glutamyl p-nitroanilide) as the donor substrate and GlyGly (glycylglycine) as the acceptor. L-GpNA can also serve as a weak acceptor and therefore cannot be used in the absence of GlyGly to measure the hydrolysis reaction. D-GpNA (D-γ -glutamyl p-nitroanalide), a stereoisomer of L-GpNA, cannot serve as an acceptor and is therefore used as a substrate to measure the hydrolysis reaction [21, 22] . However, the D-isomer of glutamate is not a physiological compound and there have been concerns as to the relevance of D-GpNA as a substrate. OU749 and its structural analogues are the only known uncompetitive inhibitors of the GGT transpeptidation reaction and the hydrolysis of D-GpNA [17, 18] . Uncompetitive inhibitors bind the γ -glutamyl intermediate (F-form) of the enzyme (Figure 1 ). In the transpeptidation reaction, the inhibitors exhibited competitive inhibition with the dipeptide acceptor GlyGly, indicating that they have a shared or overlapping binding site with GlyGly on the enzyme [17] . We have developed a novel assay (the L-glutamate release assay) that monitors GGT hydrolysis of GSH and other physiological substrates [3] .
OU749 was identified by high-throughput screening of small molecules as inhibitors of the transpeptidation reaction [17] . In the present study, we compare the potency and mechanism with which OU749 and its analogues inhibit GGT activity as measured by the transpeptidation reaction with the synthetic substrate L-GpNA, the hydrolysis reaction with the synthetic substrate
Abbreviations used: D-GpNA, D-γ-glutamyl p-nitroanalide; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; GGT, γ-glutamyl transpeptidase; GlyGly, glycylglycine; GSH, glutathione; hGGT, human GGT; L-GpNA, L-γ-glutamyl p-nitroanilide; mp, melting point. 1 To whom correspondence should be addressed (email marie-hanigan@ouhsc.edu).
Figure 1 Illustration of the GGT hydrolysis and transpeptidation reactions
The cleavage of GSH is initiated by the nucleophillic attack of the hydroxy group (OH) of threonine (Thr) on the γ -glutamyl bond of GSH forming an acyl bond with the γ -glutamyl group (γ -glu) and releasing cysteinylglycine (CysGly) of GSH. The acyl bond can be either (A) hydrolysed by water releasing glutamate (Glu) in the hydrolysis reaction or (B) transferred to a dipeptide acceptor forming a new γ -glutamyl group in the transpeptidation reaction.
D-GpNA and the physiological hydrolysis reaction with GSH as the substrate. We found that there were dramatic differences in the potency of the inhibitors dependent on the substrate used to measure hGGT activity. We also report several novel compounds that are more potent inhibitors of hGGT with the physiological substrate and evaluate the toxicity of these compounds.
EXPERIMENTAL

Synthesis of compounds
The syntheses of OU749, and Compounds 2-4, 6-11 and 13-20 have been described previously [18] . The syntheses of Compounds 21-27 are described below.
General procedure A
A concentration of 2 mmol of the appropriate phenyl acetic acid and 2 mmol of thiosemicarbazide were dissolved in 1 ml of phosphorus oxychloride and refluxed for 45 min. The reaction was then cooled to room temperature (25 • C) and 3 ml of water was added carefully. The solution was then refluxed for 4 h. The reaction mixture was filtered hot and the solid was washed with warm water. The filtrate was basified with saturated KOH and the solid was isolated by filtration. The solid was recrystallized from ethanol.
General procedure for the reduction of Compounds 21-30 to the amine
The appropriate nitro-compound (0.25 mmol) and SnCl 2 ·H 2 O (8 g/g of compound) were dissolved in 15 ml of ethanol/DCM (dichloromethane) (1:1) and heated to 40
• C. Concentrated HCl (0.2 ml) was added and the reaction was stirred for 2 h. The reaction mixture was poured into water and filtered through celite. 
Enzyme isolation
hGGT (UniProt number P19440), lacking the transmembrane domain, was expressed in Pichia pastoris and isolated as described previously [17] . The specific activity of the purified GGT was 400 units/mg. One unit of GGT activity was defined as the amount of enzyme that released 1 μmol of p-nitroaniline/min at 37
• C at pH 7.4 in the transpeptidation reaction with L-GpNA.
L-Glutamate release assay (hydrolysis of GSH)
Our L-glutamate release assay measures the production of glutamate from the hydrolysis of GSH by GGT enzyme and has been described in detail previously [3] . The concentration of the substrate, GSH, was varied from 5 to 20 μM. The concentration of the inhibitors, OU749 and its analogues, were varied from 15.6 to 250 μM. The reaction was initiated with the addition of 10 m-units of hGGT. The reaction was incubated at 37
• C and monitored continuously at 490 nm by a Bio-Rad model 680 microplate reader with Microplate Manager 5 software (Bio-Rad Laboratories). All compounds were also evaluated as inhibitors of glutamate dehydrogenase, the enzyme in the second half of the L-glutamate release assay. None of the compounds in the present study inhibited glutamate dehydrogenase.
L-GpNA transpeptidation assay
The L-GpNA transpeptidation assay has been described previously [18] . The concentration of the substrate for the transpeptidation reaction, L-GpNA (Sigma), was varied from 0.25 to 3 mM in the presence of 40 mM GlyGly (Sigma) as the acceptor. The concentration of L-GpNA was 3 mM for experiments in which the concentration of GlyGly was varied. To initiate the transpeptidation reaction, 4 m-units of GGT were added. A comparison of the activity of GGT among assays showed that the amount of hGGT that had 10 m-units of activity in the L-GpNA transpeptidation reaction had 0.868 m-unit of hGGT activity in the L-glutamate release assay.
D-GpNA hydrolysis assay
The D-GpNA hydrolysis assay was carried out as described previously [18] . Briefly, the concentration of the D-GpNA (Bachem) substrate was varied from 0.125 to 1 mM D-GpNA. The reaction was initiated with the addition of 19 m-units of GGT as determined by the L-GpNA transpeptidation assay. The reaction was incubated at 37
• C and monitored continuously at 405 nm.
Cell lines
The human renal adenocarcinoma cell line, 786-O cells (A.T.C.C. CRL-1932), were grown in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % FBS (fetal bovine serum) and penicillin/streptomycin (50 units/ml, 50 μg/ml). NIH 3T3 cells (A.T.C.C. CRL-1658) which are GGT-negative and NIH 3T3 cells expressing hGGT (described previously [23] ) were grown in DMEM/Ham's F12 medium supplemented with 5 % FBS and 0.2 mg/ml G418.
Catabolism of extracellular GSH
Both 786-O and NIH 3T3 cells were plated in 96-well plates at a density of 5×10 3 cells/well. After 24 h, the medium was changed to 100 μl of cysteine-free DMEM/Ham's F12 medium supplemented with either 20 μM GSH or 20 μM GSH and 100 μM compound 6. After 1 h, 50 μl of medium was removed and immediately acidified with 5 μl of ice-cold 43.1 % 5-sulfosalicylic acid. After 10 min on ice, the solution was neutralized with 15 μl of 1 M NaOH. The GSH concentration was determined using the method of Tietze [24] .
Cytotoxicity assays
For the cytoxicity assays, 786-O cells were plated at 10 3 cells/well in a 96-well plate in DMEM supplemented with 10 % FBS and penicillin/streptomycin (50 units/ml and 50 μg/ml). After 24 h, the medium was changed to fresh medium containing OU749 analogues. A 100 mM stock of OU749 and each of its analogues were made in DMSO and then diluted in DMEM. Control wells were treated with equivalent concentrations of DMSO. Cell viability was determined 72 h after the addition of the inhibitors using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay [25] .
Data analysis
In each experiment the assays were run in triplicate. Each inhibitor was evaluated in two or more independent experiments. Double reciprocal plots were generated to assess data quality and determine the correct rate equation for data fitting. Data were fitted using the proper rate equation and the Marquardt-Levenberg algorithm supplied with the Enzfitter program (BIOSOFT). Kinetic parameters with S.E.M. values were estimated using a simple weighting method.
Data adhering to Michaelis-Menten kinetics were fitted to eqn (1). Data for competitive, uncompetitive and non-competitive inhibition were fitted to eqns (2) , (3) and (4) respectively. Data for the dependence of V max and V max /K D-GpNA on the concentration of activator were fitted using eqn (5) [26] .
In eqns (1-4), v and V max are the initial and maximum rates respectively, K a is the Michaelis constant for the varied substrate, and K is and K ii are slope and intercept inhibition constants respectively. In eqn (5), a is the value of V max or V max /K D-GpNA at zero activator/inhibitor, K ID is the activation or inhibition constant, and K IN is a constant that causes the parameter to go to a constant value at infinite concentrations of X, the activator/inhibitor. The
For the toxicity of OU749 and its analogues in 786-O cells, all determinations were performed in triplicate. The LD 50 of each compound and the S.D. were calculated with a Prism log (inhibitor) compared with a normalized response (variable slope) curve fit (Prism, GraphPad Software).
Structural model of the OU749 interaction with hGGT
A refined structural model of hGGT described previously and based on crystallographic templates of bacterial GGT was used [27] . The model of OU749 was built using the program Insight II and manually fitted into the structural model of hGGT. Then the complex structure was energy minimized using the CNS program suite [28] . The value of the total energy after 300 cycles decreased from 113 350 to 11 866 calories.
RESULTS
hGGT can catalyse both a hydrolysis reaction and a transpeptidation reaction ( Figure 1 ). When present at high concentrations, L-amino acids and dipeptides can serve as acceptors in the transpeptidation reaction. GSH has an L-γ -glutamyl moiety, and the free amino group on the α carbon might serve as an acceptor. Our initial studies were designed to clarify whether GSH serves as both a donor substrate and an acceptor. The α carbon of D-amino acids is unable to act as an acceptor, therefore the substrate D-GpNA functions as a donor substrate, but cannot function as an acceptor [21] . Kinetic analyses of D-GpNA cleavage in the presence of GSH showed that GSH was competitive with D-GpNA. These data reveal that GSH competes for the γ -glutamyl donor-binding site, but did not function as an acceptor with a D-γ -glutamyl donor ( Figure 2A ). The K m of D-GpNA was 160 + − 20 μM. The K is of GSH was 10 + − 1.2 μM. Kinetic analyses were also performed with L-GpNA in the presence of GSH. Analysis of the GSH inhibition of the transpeptidation reaction with LGpNA and the acceptor GlyGly showed that GSH is a noncompetitive inhibitor of both ( Figures 2B and 2C ). The K m of L-GpNA in the transpeptidation reaction is 1.2 + − 0.1 mM. In the presence of 40 mM GlyGly, GSH inhibited L-GpNA in the transpeptidation reaction with K ii = 1.70 + − 0.02 mM and K is = 1.40 + − 0.01 mM. When evaluated with GlyGly in the presence of 3 mM L-GpNA, GSH was a non-competitive inhibitor of the transpeptidation reaction with K ii = 3 + − 0.5 mM and K is = 0.8 + − 0.1 mM ( Figure 2C ). This non-competitive inhibition profile indicates that GSH binds both the free enzyme and the F-form, competing with both the donor (L-GpNA) and the acceptor (GlyGly) substrate when GSH is present at high (millimolar) concentrations.
We then analysed the interaction between GSH and L-GpNA in the absence of GlyGly. Both GSH and L-GpNA are donor substrates. They both have an L-glutamate as the γ -glutamyl group and, thus, can also serve as acceptors. The complex data obtained from these experiments were most clearly presented as a Dixon plot ( Figure 2D ). Initial velocity analysis of GSH inhibition of the L-GpNA cleavage is shown for two concentrations of L-GpNA (0.25 and 3 mM). In the presence of 3 mM L-GpNA, the Dixon plot was linear with GSH acting as a very weak inhibitor of L-GpNA as a donor substrate ( Figure 2D ). The K m of L-GpNA in these studies was 0.83 + − 0.06 mM. The K is of GSH was 0.073 + − 0.006 mM. However, the biphasic nature of the Dixon plot at 0.25 mM L-GpNA indicates that GSH has two modes of action under these reaction conditions ( Figure 2D ). At concentrations up to 40 μM, GSH is a competitive inhibitor of L- GpNA ( Figure 2E ). At concentrations of GSH above 0.31 mM, the Dixon plot showed a second phase, in which GSH is competitive with both L-GpNA as a donor substrate and with L-GpNA as an acceptor. Thus at high concentrations GSH can act as an acceptor substrate, confirming data from Abbott et al. [29] . In the L-glutamate release assay, GSH is used as a substrate over the range 5-20 μM. Under these conditions, GSH is functioning solely as a donor substrate. Therefore data from the Lglutamate release assay is a direct measurement of the hydrolysis of the γ -glutamyl bond of GSH.
Previous studies had shown that OU749 was an uncompetitive inhibitor of hGGT, binding to the γ -glutamyl-enzyme intermediate (the F-form of the enzyme), while competing with the acceptor in the transpeptidation reaction [17, 18] . We assayed a large series of OU749 analogues and evaluated their effect on the hydrolysis of the acyl bond of the L-γ -glutamyl-enzyme intermediate (GSH as substrate), the hydrolysis of the acyl bond of the D-γ -glutamyl-enzyme intermediate (D-GpNA as a substrate) and the transfer of the L-γ -glutamyl-enzyme moiety to an acceptor (L-GpNA as the substrate and GlyGly as the acceptor).
OU749 and a series of its analogues bearing para-substitutions on the benzosulfonamide ring were the first set of compounds that were analysed ( Table 1 ). All of the compounds were uncompetitive inhibitors of GSH. They were also uncompetitive inhibitors of D-GpNA and L-GpNA, but competitive inhibitors of GlyGly, as previously reported for OU749 [17, 18] . Substituting an amine in the para position increased the potency of inhibition of GSH hydrolysis, whereas substituting a methyl group at this position decreased the potency. Bulky groups at the para position also impeded the function of the compound as an inhibitor of GSH hydrolysis. A comparison of the inhibition of the hydrolysis of D-GpNA by these same compounds showed that they were more potent inhibitors of the hydrolysis of the D-γ -glutamyl enzyme acyl bond (D-GpNA substrate) than the L-γ -glutamyl enzyme acyl bond (GSH substrate), but the rank order of potency remained the same (Table 1) . Even though each of these compounds was an uncompetitive inhibitor of L-GpNA in the transpeptidation reaction, their potency correlated more directly with their competitive inhibition of the acceptor GlyGly than their inhibition of the cleavage of the L-γ -glutamyl acyl bond (GSH hydrolysis). This may be due to the fact that acyl transfer to an acceptor is more rapid than hydrolysis of the acyl bond [19] . Therefore competing with GlyGly would have a more potent effect on the rate of the reaction than inhibition of hydrolysis of the acyl bond. The methyl-substituted OU749 analogue, Compound 2, was previously identified as a more potent inhibitor of hGGT based on its inhibition of the L-GpNA transpeptidation reaction [18] . However, Compound 2 was 1.3-fold less potent than OU749 in inhibiting the hGGTmediated hydrolysis of GSH, the physiological reaction catalysed by hGGT (Table 1 ). In contrast with Compound 2 and the other para-substituted OU749 analogues, Compound 21, with a p-amine, was 3.6-fold more potent than OU749 in inhibiting the catabolism of GSH. Therefore we classified Compound 21 as a new lead compound from among this series of OU749 analogues (Table 1 ). These findings demonstrate that data from the standard L-GpNA transpeptidation assay can be misleading when optimizing inhibitors of hGGT for use in vivo.
On the basis of the improved potency of Compound 21 compared with OU749 in inhibiting the hydrolysis of GSH, we synthesized of a series of structural analogues of Compound 21 in which the distal benzene ring was modified ( Table 2 ). All of these compounds were found to be uncompetitive inhibitors of the hydrolysis of GSH, D-GpNA and L-GpNA, but competitive inhibitors of GlyGly. The kinetic data for Compound 22 are shown in Figure 3 . As uncompetitive inhibitors, these compounds bind the γ -glutamyl-enzyme intermediate (F-form) with all three donor substrates. The rank order of potency with which these compounds inhibit the hydrolysis of GSH compared with D-GpNA differs ( Table 2 ). These data indicate that there are differences in the F-form of the enzyme dependent on the stereochemistry of the bound glutamate group (L-glutamate in GSH and D-glutamate in D-GpNA), and that these differences affect the potency with which this class of compounds inhibits the reaction. Compound 22 and its analogues are uncompetitive inhibitors of L-GpNA ( Figure 3C ). The F-form of the enzyme is the same with either GSH or L-GpNA as substrates, because both have an L-γ -glutamyl group. However, as observed for the compounds in Table 1 (Tables 1 and 2 ). Compound 22 has a methyl group in the para position on the distal benzene ring. Compound 23, has an amine group in the para position. OU749 analogues with a small neutral or slightly charged group on the distal benzene ring paired with an amine group para on the benzosulfonamide ring are more potent inhibitors of the catabolism of GSH by hGGT than Compound 21.
In the present study, we also evaluated a series of OU749 analogues with chlorine or benzene substitutions on the sulfobenzene ring as inhibitors of GSH hydrolysis (Table 3) . These compounds had previously been evaluated as inhibitors of D-GpNA hydrolysis and the transpeptidation reaction with L-GpNA, and had been shown to be potent inhibitors of hGGT1 transpeptidation [18] . Compound 3, which has a chlorine in the meta position on the benzosulfonamide ring, was 5.6-fold more potent than OU749 in inhibiting GSH hydrolysis (K ii values of 67 + − 6 μM and 376 + − 50 μM respectively). Interestingly, this same substitution had no effect on the inhibition of the cleavage of D-GpNA relative to that observed for the unsubstituted OU749 core (Compound 3 K ii = 75 + − 2 μM and OU749 K ii = 73 + − 9 μM). Similar to OU749, all of the compounds in Table 3 were uncompetitive inhibitors of the three donor substrates (GSH, D-GpNA and L-GpNA) and competitive inhibitors of GlyGly. The kinetic data for Compound 3 are shown in Figure 4 . Remarkably, shifting the chlorine substituent to the para position on the benzosulfonamide ring (Compound 10) virtually abolished the inhibitory potency of the OU749 core structure in the hydrolysis of GSH. This result is in marked contrast with the enhanced GSH inhibition observed when an amine group was substituted at this position (OU749 and Compound 21, Table 1 ). When chlorine was present at both the meta and para positions, the para chlorine substitution counteracted the enhanced potency gained by a chlorine in the meta position (Compounds 3 and 8, Table 3 ). Addition and relative placement of the chlorines on the sulfobenzene ring (Table 3, compounds with chlorines in the para position were potent inhibitors of the transpeptidation reaction (L-GpNA and GlyGly), while weak to ineffective inhibitors of the hydrolysis of GSH (Table 3 , Compounds 4, 8 and 10). Compound 3 is the most potent inhibitor of hGGT among all of the compounds in Table 3 and among all of the OU749 analogues we have tested to date. Two compounds containing a bulky hydrophobic group on the benzosulfonamide ring were also synthesized and evaluated as inhibitors of GSH hydrolysis. A 1-or 2-napthylsulfonamide ring replaced the benzosulfonamide ring (Table 3 ). Both compounds inhibited the catabolism of GSH by an uncompetitive mechanism, the same mechanism observed with OU749 and its other analogues (Figure 4 ). Compound 6, the 1-napthylsulfonamide derivative, was 4-fold more potent than OU749 in inhibiting the catabolism of GSH (K ii values of 96 + − 2 and 376 + − 50 μM respectively). Compound 30, a 2-napthylsulfonamide derivative, was evaluated to determine whether shifting the bulky hydrophobic group to a more para position would decrease the potency, as was observed for the chloro-substituted OU749 analogues. Compound 30 was 2.1-fold less potent than Compound 6 in inhibiting the catabolism of GSH (206 + − 37 compared with 96 + − 2 μM) ( Table 3) . Compound 30 was also less potent than Compound 6 in inhibiting both hydrolysis and transpeptidation reactions.
We next evaluated a series of nitro-substituted compounds for their effect on the catabolism of GSH by hGGT. Previously, we observed that this series of OU749 derivatives with a nitro-substitution in the para position on the benzosulfonamide ring were V-type activators of the hydrolysis of D-GpNA and uncompetitive inhibitors of the L-GpNA transpeptidation reaction of hGGT (Table 4 , Compounds 11 and 13-19) [18] . V-type activators increase the V max of the reaction. Using the Lglutamate release assay, we discovered that these compounds also accelerated the catabolism of GSH (Table 4 ). The kinetic analysis of the activation profiles of these compounds revealed that they are V-type activators of the hydrolysis of GSH, as was observed with D-GpNA. The kinetic data for Compound 14 are shown in Figure 5 . The V max increases with increasing concentration of Compound 14. Concomitantly, the K m of GSH increases to a greater extent than the V max. An observed increase in the V max near saturating concentrations of the donor substrate with inhibition of V/K m correlates with other V-type activators [30] . None of these compounds activated the transpeptidation reaction, instead they inhibited it (Table 4) . If the compounds in Table 4 were accelerating the hydrolysis of GSH by acting as acceptors, a decrease in the rate of glutamate release would be observed in the L-glutamate release assay because glutamate would be converted into a new γ -glutamyl compound before release from the enzyme. The accelerated release of glutamate in the presence of Compound 14 demonstrates that Compound 14 is accelerating the hydrolysis of the acyl bond and not accelerating the reaction by acting as an acceptor. The potency with which the nitro compounds activate the reaction is similar for both the hydrolysis of GSH and D-GpNA, with only minor discrepancies in the rank order with which they accelerate the reactions (Table 4 ). These data indicate that the nitro compounds accelerate the hydrolysis of the acyl bond in the F-form of the enzyme with similar potency, regardless of whether an L-glutamate or D-glutamate is bound in the F-form of the enzyme. Among the nitro compounds, the only compound that inhibited both the hydrolysis reaction and transpeptidation reaction was Compound 20 (Table 4 ) [18] . Compound 20 was shown previously to inhibit the hydrolysis of D-GpNA as a competitive inhibitor [18] . In our current analyses, we found that it also acted as a competitive inhibitor of the catabolism of GSH (results not shown), indicating that this compound binds differently than the other OU749 analogues, competing with the donor substrate binding to the free enzyme. On the basis of these analyses of hGGT inhibition with a physiological substrate (GSH), we identified three new lead compounds (Compounds 3, 6 and 22) from three distinct classes of OU749 structural derivatives that are more potent inhibitors than OU749. To assess their potential clinical utility, we evaluated the toxicity of our inhibitors towards proliferating cells in culture ( Table 5 ). The glutamine analogue acivicin is a potent inhibitor of hGGT, but it is too toxic for clinical use [16] . We have reported previously that OU749 is less toxic than acivicin [17] . As shown in Table 5 , OU749 is almost 100-fold less toxic than acivicin. Data from the present study reveal that, of the three optimized OU749 analogues evaluated, each was considerably less toxic than OU749. Compound 6, which was almost four times more potent as an inhibitor of hGGT hydrolysis relative to OU749 (K ii of 96 + − 2 μM compared with 376 + − 50 μM respectively), was also more than 16-fold less toxic than OU749, with an LD 50 of 2090 + − 20 μM (Tables 3 and 5) . As a result, this 1-naphthylsulfonamide analogue of OU749 is our new lead compound for inhibiting hGGT.
All of the kinetic studies were conducted with soluble purified hGGT. To assess inhibition under in vivo conditions, we evaluated the ability of Compound 6 to inhibit membrane-bound hGGT expressed on the surface of the hGGT-positive cell line 786-O. We measured the rate of cleavage of 20 μM GSH by determining the concentration of GSH remaining in the medium after 1 h in the presence or absence of Compound 6 ( Figure 6 ). Compound 6 (100 μM) blocked the hGGT catabolism of GSH by 51 % (Figure 6 ). To confirm that the reduced catabolism of GSH was due to inhibition of hGGT, we repeated the experiment using a stably transfected hGGT-positive cell line (NIH 3T3 GGT ) and its GGTnegative parental line (NIH 3T3). The control GGT-negative NIH 3T3 cells were unable to metabolize extracellular GSH ( Figure 6 ).
Constitutive expression of hGGT in NIH 3T3
GGT cells resulted in a dramatic increase in the cleavage of extracellular GSH ( Figure 6 ). Compound 6 reduced the ability of NIH 3T3
GGT to metabolize GSH in the medium by 59 %, demonstrating that this new lead inhibitor is capable of efficiently blocking the enzymatic activity of hGGT in its cellular context.
DISCUSSION
To develop potent inhibitors of hGGT that can be used clinically, it is essential that compounds be evaluated as inhibitors of the physiological hGGT reaction. This can now be performed with GSH as the substrate in our L-glutamate release assay. GSH is the most abundant substrate of hGGT in vivo. The L-glutamate release assay allows for kinetic analysis of compounds as inhibitors of hGGT-mediated GSH catabolism. Most studies of hGGT inhibition have been conducted using the L-GpNA transpeptidation assay with millimolar concentrations of the synthetic γ -glutamyl donor substrate (L-GpNA) and the acceptor (GlyGly). Screening the analogues of OU749 in the present study with the transpeptidation assay would have identified Compounds 2-4 and 8 as new lead inhibitors. Our analysis of their inhibition of the hydrolysis of GSH showed that Compounds 2, 4 and 8 were much less potent that OU749. In fact, Compound 8 had no detectable inhibitory activity towards the hydrolysis of GSH. In contrast, Many of the compounds assessed in the present study inhibited the catabolism of GSH, some accelerated the reaction and some had no effect. There was no consistent correlation between the effect of a compound on the catabolism of GSH and its effect on the hydrolysis of D-GpNA, or on the transpeptidation reaction with L-GpNA as the substrate and GlyGly as the acceptor. There are features of each of the three assays which provided unique insights into the mechanism by which these uncompetitive inhibitors alter the rate of the hGGT reaction. The results of the present study show that at the physiological concentrations of GSH used in the L-glutamate release assay, the reaction catalysed by hGGT is the hydrolysis of the γ -glutamyl bond of GSH. The γ -glutamyl enzyme intermediate has an L-glutamate in the active site bound by an acyl bond to the oxygen on the side chain of Thr 381 [19] . Free glutamate is detected when it is released as the second product of the reaction. In the assay measuring the hydrolysis of D-GpNA, there is a D-γ -glutamyl enzyme intermediate. In assays with either L-GpNA or D-GpNA as substrates, the release of p-NA is the product that is quantifiably measured. Use of L-GpNA and GlyGly as the donor and acceptor substrates respectively results in a transpeptidation reaction, with the production of a γ -glutamylacceptor compound as the second product. This assay provides insight into the interaction of the test compound with the acceptorbinding site. Therefore data from a L-GpNA transpeptidation reaction can serve a complementary role with data from a GSH hydrolysis reaction to provide information regarding the relative contribution of the acceptor in accelerating acyl transfer or in trapping the acyl-enzyme intermediate by the uncompetitive inhibitor.
In our initial report of the discovery of OU749 as an inhibitor of hGGT, we demonstrated that it acts as an uncompetitive inhibitor of the transpeptidation reaction with L-GpNA as a substrate, binding the F-form of the enzyme and competing with the acceptor GlyGly [17] . With the exception of Compounds 19 and 20, all of the OU749 analogues evaluated in the present study showed the same mechanism of inhibition of the transpeptidation reaction.
Our primary goal is to enhance the potency of OU749 as an inhibitor of GSH hydrolysis. OU749 is a weaker inhibitor of hydrolysis of the acyl bond of the γ -glutamyl enzyme intermediate when GSH is the substrate and an L-γ -glutamyl group occupies the donor site than when D-GpNA is the substrate and a D-γ -glutamyl group occupies the active site (OU749, Table 1 ). In the first set of compounds analysed, addition of substituents in the para position on the sulfobenzene ring showed that an amine group enhanced the potency of OU749 as an inhibitor of GSH hydrolysis, whereas the addition of bulky uncharged groups reduced its potency. Further analysis of modifications to the benzosuflonamide ring (Table 3) showed that chlorine in the meta position (Compound 3) is preferential to a chlorine in the para (Compound 10), para and ortho (Compound 4), or para and meta positions (Compound 8). The chlorine in the para position could be eliciting an electrostatic repulsion with a charged amino acid or dipoles within the active site, thereby diminishing the affinity of the OU749 analogue and its inhibitory potency. The compounds had the same rank order of potency with which they inhibited GSH and D-GpNA hydrolysis, suggesting that, although substituents in the para position do not change the orientation of the compound relative to the acyl bond, they either alter the affinity with which the compounds bind the enzyme or alter the electrophilicity of the sulfonamide group. Han et al. [12] synthesized and evaluated a series of γ -glutamyl phosphono diesters as inhibitors of hGGT. They proposed that the mechanism of inhibition by these compounds included the phosphonate diesters reacting covalently with the catalytic threonine residue of GGT. We propose that the sulfonamide of OU749 and its analogues interact electrostatically with the acyl bond of the γ -glutamyl-enzyme intermediate. Modifications to the sulfobenzene rings, such as addition of chlorines or a benzyl group (Table 3) may alter the strength of interaction between the sulfonamide and the catalytic nucleophile of hGGT and/or the acyl bond. An homology model of hGGT shows the proposed binding site of OU749 (Figure 7 ). There is no crystal structure of any eukaryotic GGT. The model of hGGT is based on crystallographic templates of bacterial GGT and includes glutamate bound in the active site forming an acyl bond with Thr 381 . Modelling OU749 into the active site of the γ -glutamyl enzyme intermediate shows that the oxygen of the sulfonamide group of OU749 is 3.1Å (1 Å = 0.1 nm) from the oxygen of Thr 381 , which forms the acyl bond ( Figure 7) . The sulfobenzene ring is located in a hydrophobic pocket formed by the side chains of Phe 540 , Leu 402 , Tyr 403 and Phe 433 . The sulfobenzene ring is in close proximity to Glu 432 , which may interact with the para amine group stabilizing the position of the analogues with an amine para on the sulfobenzene ring. Bulky constitutents at this para position, including chlorine may alter the affinity with which these para-substituted analogues bind the enzyme.
In contrast, addition of a benzene group to the sulfobenzene ring not only altered the potency of the compounds, but also elicited different effects on the hydrolysis of GSH compared with D-GpNA ( Table 3) Addition of a p-nitro on the sulfobenzene ring resulted in a compound that accelerated the hydrolysis reaction, but inhibited the transpeptidation reaction (Table 4 ). In the transpeptidation reaction, GlyGly accelerates acyl transfer of the γ -glutamyl group to the free amine of GlyGly. Therefore, in the transpeptidation reaction, OU749 analogues inhibit the transpeptidation reaction by two mechanisms: blocking GlyGly from the acceptor site and limiting access to the L-γ -glutamyl acyl bond. One possible explanation for this effect is that the nitro-substituted OU749 analogues bind to the GlyGly site, inhibiting the transpeptidation reaction and destabilizing the acyl bond to allow a more facile attack by water, thus promoting hydrolysis. We have previously shown that GlyGly increases the L-GpNA cleavage rate by 22-fold [18] . Addition of a p-nitro OU749 analogue increased the D-GpNA cleavage rate by only 5-fold [18] . This difference in the rate of acceleration of hydrolysis of the acyl bond, which is observed with GSH and D-GpNA, is insufficient to offset the decreased rate of cleavage of L-GpNA due to the absence of GlyGly, resulting in an apparent inhibition of the transpeptidation reaction. All of the inhibitors and the activators are competitive inhibitors of GlyGly in the transpeptidation reaction, indicating that the inhibitors are binding at the acceptor site or at a site that overlaps with the acceptor site, thus blocking GlyGly from binding. The binding site of the acceptors is not known.
Modifications to the distal benzene ring of OU749 decreased the K is up to 11-fold as competitive inhibitors of GlyGly (Compound 29, Table 2 ). Two of the most potent inhibitors of GlyGly bear chlorines in the para position (Compound 28), or the meta and para positions (Compound 29). However, there was no correlation between the potency of these compounds as competitive inhibitors of GlyGly and their potency in inhibiting the hydrolysis of GSH. We analysed the effect of modifications to the distal benzene ring of the amine OU749 structural analogues on the inhibition of hydrolysis of GSH. The data revealed that a small neutral (Compound 22 and Compound 24), small positive (electron donating, Compound 23) or small slightly negatively charged group (Compound 21) on the distal benzene ring was favourable for hGGT inhibition, whereas a bulky group (Compounds 26-29) on the distal benzene ring diminished the inhibitory potency of the amine OU749 analogues (Table 2) . Our model suggests the presence of a hydrogen bond between Lys 562 and the carboxylate group on the distal benzene ring of OU749 which are separated by a distance of only 3.08 Å (Figure 7) . Hu et al. [31] mutated Lys 562 to an asparagine or glutamine residue and found a significant reduction in the hydrolysis and transpeptidation activity of hGGT as well as reduced inhibition by OU749. Using a model of hGGT based on the crystal structure of Escherichia coli GGT they examined possible binding interactions between GGT and OU749. They also proposed a hydrogen bond between Lys 562 and the carboxylate group on the distal benzene ring of OU749. Our model indicates that the distal benzene ring of OU749 interacts with the side chains of His 81 through pi-stacking on one side and makes a hydrophobic contact with Ile 541 on the other side. Small neutral or small charged groups para on the distal benzene ring (Compound 22, Compound 23 and Compound 24) may be interacting with a hydrophilic residue such as Asn 79 thereby stabilizing inhibitor binding. In contrast, bulky groups may shift the orientation of the inhibitor thereby destabilizing its interaction with the acyl bond.
The toxicity of the OU749 analogues was not related to their potency as inhibitors of hGGT activity. Inhibitors of GGT that are glutamine analogues not only inhibit hGGT, but also inhibit other glutamine-dependent enzymes, which leads to the neurotoxicity observed with acivicin [16, 32, 33] . OU749 is not a glutamine analogue and has been shown to be less toxic than acivicin [17] . The development of OU749 structural derivatives has led to the discovery of more potent inhibitors that are even less toxic than OU749. Compound 3 was the most potent hGGT inhibitor and was 3-fold less cytotoxic than OU749 with an LD 50 of 375 μM (Tables 3 and 6 ). Compound 6 was the third most potent hGGT inhibitor (approximately 4-fold more potent than OU749) and exhibited the least cytotoxicity with an LD 50 of approximately 2100 μM (Tables 4 and 6 ).
The ability to measure inhibition of the extracellular catabolism of GSH by hGGT is crucial for inhibitor optimization, as the physiological reaction is the hydrolysis of GSH on the cell surface. Our most potent and least cytotoxic OU749 analogue, Compound 6, was also found to inhibit hGGT in vivo, blocking the cleavage of extracellular GSH. These data validate the approach of identifying inhibitors of the physiological hGGT GSH hydrolysis reaction using our L-glutamate release assay. The optimization of compounds as potent non-toxic inhibitors of hGGT will lead to the development of therapeutics for cancer, cardiovascular disease and pulmonary diseases, such as asthma.
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